162 related articles for article (PubMed ID: 3117606)
1. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors.
Lightman S; Rechthand E; Terubayashi H; Palestine A; Rapoport S; Kador P
Diabetes; 1987 Nov; 36(11):1271-5. PubMed ID: 3117606
[TBL] [Abstract][Full Text] [Related]
2. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
Das A; Frank RN; Zhang NL; Samadani E
Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
[TBL] [Abstract][Full Text] [Related]
3. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
Vinores SA; Campochiaro PA
Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
[TBL] [Abstract][Full Text] [Related]
4. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats.
Vinores SA; McGehee R; Lee A; Gadegbeku C; Campochiaro PA
J Histochem Cytochem; 1990 Sep; 38(9):1341-52. PubMed ID: 2117624
[TBL] [Abstract][Full Text] [Related]
5. The polyol pathway in retinal microangiopathy.
Robison WG; Kinoshita JH; Kador PF
Drugs; 1986; 32 Suppl 2():19-22. PubMed ID: 3098542
[TBL] [Abstract][Full Text] [Related]
6. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
Tilton RG; Pugliese G; LaRose LS; Faller AM; Chang K; Province MA; Williamson JR
J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase activity and basement membrane thickening.
Frank RN
Metabolism; 1986 Apr; 35(4 Suppl 1):35-40. PubMed ID: 3083207
[TBL] [Abstract][Full Text] [Related]
8. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
Datiles M; Fukui H; Kuwabara T; Kinoshita JH
Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
[TBL] [Abstract][Full Text] [Related]
9. The effect of aldose reductase inhibitor, statil, on hyperpermeability of iridial vessels in experimental galactosemic rats.
Terubayashi H; Akagi Y
Jpn J Ophthalmol; 1989; 33(3):343-7. PubMed ID: 2507812
[TBL] [Abstract][Full Text] [Related]
10. Prevention of nerve edema and increased blood-nerve barrier permeability-surface area product in galactosemic rats by aldose reductase or thromboxane synthetase inhibitors.
Wadhwani KC; Caspers-Velu LE; Murphy VA; Smith QR; Kador PF; Rapoport SI
Diabetes; 1989 Nov; 38(11):1469-77. PubMed ID: 2559867
[TBL] [Abstract][Full Text] [Related]
11. Permeability changes at blood-retinal barrier in diabetes and effect of aldose reductase inhibition.
Lightman S; Pinter G; Yuen L; Bradbury M
Am J Physiol; 1990 Sep; 259(3 Pt 2):R601-5. PubMed ID: 2118733
[TBL] [Abstract][Full Text] [Related]
12. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor.
Robison WG; Kador PF; Kinoshita JH
Science; 1983 Sep; 221(4616):1177-9. PubMed ID: 6612330
[TBL] [Abstract][Full Text] [Related]
13. Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition.
Bank N; Coco M; Aynedjian HS
Am J Physiol; 1989 Jun; 256(6 Pt 2):F994-9. PubMed ID: 2500030
[TBL] [Abstract][Full Text] [Related]
14. [Diabetic changes in pupillary reactions and iris histology. No. 3. The role of aldose reductase inhibitor to iridal vessel hyperpermeability of galactose-fed rats].
Kador PF; Kinoshita JH; Terubayashi H; Akagi Y; Kador PF; Kinoshita JH
Nippon Ganka Gakkai Zasshi; 1988 Oct; 92(10):1577-81. PubMed ID: 3145680
[No Abstract] [Full Text] [Related]
15. Electron microscopic immunocytochemical evidence for the mechanism of blood-retinal barrier breakdown in galactosemic rats and its association with aldose reductase expression and inhibition.
Vinores SA; Van Niel E; Swerdloff JL; Campochiaro PA
Exp Eye Res; 1993 Dec; 57(6):723-35. PubMed ID: 8150024
[TBL] [Abstract][Full Text] [Related]
16. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs.
Datiles MB; Kador PF; Kashima K; Kinoshita JH; Sinha A
Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2201-4. PubMed ID: 2122961
[TBL] [Abstract][Full Text] [Related]
17. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
Yue DK; Hanwell MA; Satchell PM; Handelsman DJ; Turtle JR
Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
[TBL] [Abstract][Full Text] [Related]
18. Aldose reductase inhibitors and prevention of galactose cataracts in rats.
Unakar N; Tsui J; Johnson M
Invest Ophthalmol Vis Sci; 1989 Jul; 30(7):1623-32. PubMed ID: 2545646
[TBL] [Abstract][Full Text] [Related]
19. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat.
Robison WG; Kador PF; Akagi Y; Kinoshita JH; Gonzalez R; Dvornik D
Diabetes; 1986 Mar; 35(3):295-9. PubMed ID: 3081393
[TBL] [Abstract][Full Text] [Related]
20. Permeability of the blood-retinal and blood-aqueous barriers in galactose-fed rats.
Caspers-Velu LE; Wadhwani KC; Rapoport SI; Kador PF
J Ocul Pharmacol Ther; 1995; 11(3):469-87. PubMed ID: 8590278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
